Altre lingue Gencurix Inc.

Azioni

A229000

KR7229000005

Prezzo di chiusura Korea S.E. Altri mercati azionari 00:00:00 16/05/2024			Variaz. 5gg	Var. 1 gen.
3.170 ^KRW	-0,94%		0,00%	-49,04%

15/04	J&L Agent Co., Ltd. e altri acquirenti hanno completato l'acquisizione della partecipazione del 4,97% in NGeneBio Co., Ltd. (KOSDAQ:A354200) da Gencurix Inc. (KOSDAQ:A354200) da Gencurix Inc. (KOSDAQ:A229000).	CI
2023	Gencurix Inc. Ottiene l'approvazione per la diagnostica complementare del test di mutazione Egfr basato su Pcr digitale	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3 billion.	15/04
J&L Agent Co., Ltd. and other buyer agreed to acquire 4.97% stake in NGeneBio Co., Ltd. from Gencurix Inc. for KRW 3.2 billion.	03/04
Gencurix Inc. announced that it has received KRW 3.99999552 billion in funding from HLB PANAGENE Co., LTD.	25/01
HLB PANAGENE Co., LTD. announced that it has received KRW 2 billion in funding from Gencurix Inc.	24/01
HLB PANAGENE Co., LTD. announced that it expects to receive KRW 2 billion in funding from Gencurix Inc.	17/01
Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	28/12
Abion Inc. announced that it expects to receive KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	20/12
Gencurix Inc. Obtains Approval for Companion Diagnostic of Digital Pcr-Based Egfr Mutation Test	14/06/23
Gencurix Announces Clinical Research Results at Asco Demonstrating Outstanding Performance of GenesWellBCT Compared to Global Best-Selling Test, Oncotypedx	07/06/23
Gencurix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23
Gencurix Announces Korean and Japanese Cancer Patients' 15-Year Follow-Up Prognostic Test Clinical Results	10/05/23
Gencurix to Raise 28 Billion Won From Stock Offering	17/01/23
Gencurix Inc. announced that it has received KRW 26.9999819 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Aju IB Investment Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm and other investors	08/06/21
Gencurix Inc. announced that it expects to receive KRW 26.9999819 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Aju IB Investment Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm and other investors	31/05/21
Gencurix Inc. announced that it has received KRW 2 billion in funding	31/08/20
Gencurix Inc. announced that it expects to receive KRW 2 billion in funding	21/08/20
Gencurix Inc. agreed to acquire a 41% stake in Nano Bio Life Co., Ltd. from Soo-kyung Kim, Jihye Cheon, Injoong Kim, Ki-moon Song, Jichul Hyun and Sujin Lee for KRW 3.7 billion.	21/08/20
Gencurix Inc. Receives U.S. Food and Drug Administration's Emergency Use Authorization for Its GenePro SARS-CoV-2 Test	24/06/20
Gencurix to Release New Coronavirus Diagnostic Kit in the EU	20/03/20
Gencurix Inc. announced that it has received KRW 1.299999 billion in funding from AJU Capital Co., Ltd., Samsung Securities Co. Ltd., Investment Arm	11/02/20

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Gencurix Inc.

Azioni

A229000

KR7229000005

Altre lingue

Filtri